Extracted from this filing and checked against the source text.
Equity Issuances
SEC 8-K Item 3.02/3.03
confidence 0.9
Transcode Therapeutics, Inc. issued 1,136,364 shares of a new series of non-voting convertible preferred stock of preferred stock to Unleash Immuno Oncolytics, Inc. for one-time payment of 1,136,364 shares of a new series of non-voting convertible preferred stock.
- Security
- preferred stock
- Shares
- 1,136,364 shares of a new series of non-voting convertible preferred stock
- Purchaser
- Unleash Immuno Oncolytics, Inc.
- Consideration
- one-time payment of 1,136,364 shares of a new series of non-voting convertible preferred stock
Exact text from the filing
Unleash will receive a one-time payment of 1,136,364 shares of a new series of non-voting convertible preferred stock of TransCode, convertible into an equal number of shares of common stock of TransCode (the “Preferred Stock”).
View on SEC.gov
Governance Changes
SEC 8-K Item 5.03/5.05/5.06
confidence 0.9
Transcode Therapeutics, Inc.: Filed Certificate of Designation for Series C Non-Voting Convertible Preferred Stock, establishing its preferences, rights, and limitations (effective 2026-03-02).
- Change
- charter amendment
- Effective
- 2026-03-02
Exact text from the filing
On March 2, 2026, the Company filed a Certificate of Designation of Preferences, Rights and Limitations (the “Certificate of Designation”) of the Series C Non-Voting Convertible Preferred Stock, par value $0.0001 per share, (the “Series C Preferred Stock”) with the Secretary of State of the State of Delaware
View on SEC.gov